JP2014503191A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503191A5
JP2014503191A5 JP2013537894A JP2013537894A JP2014503191A5 JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5 JP 2013537894 A JP2013537894 A JP 2013537894A JP 2013537894 A JP2013537894 A JP 2013537894A JP 2014503191 A5 JP2014503191 A5 JP 2014503191A5
Authority
JP
Japan
Prior art keywords
synuclein
disease
pharmaceutical composition
ice
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537894A
Other languages
English (en)
Japanese (ja)
Other versions
JP6006908B2 (ja
JP2014503191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059463 external-priority patent/WO2012061785A2/en
Publication of JP2014503191A publication Critical patent/JP2014503191A/ja
Publication of JP2014503191A5 publication Critical patent/JP2014503191A5/ja
Application granted granted Critical
Publication of JP6006908B2 publication Critical patent/JP6006908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537894A 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用 Expired - Fee Related JP6006908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41085610P 2010-11-05 2010-11-05
US41085210P 2010-11-05 2010-11-05
US61/410,852 2010-11-05
US61/410,856 2010-11-05
PCT/US2011/059463 WO2012061785A2 (en) 2010-11-05 2011-11-04 Ice inhibiting compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2014503191A JP2014503191A (ja) 2014-02-13
JP2014503191A5 true JP2014503191A5 (enExample) 2014-12-18
JP6006908B2 JP6006908B2 (ja) 2016-10-12

Family

ID=46024857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Country Status (4)

Country Link
US (3) US9116157B2 (enExample)
EP (2) EP2635906A4 (enExample)
JP (2) JP6006908B2 (enExample)
WO (2) WO2012061785A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN110545835A (zh) 2016-12-23 2019-12-06 A·勒布朗 Caspase-1抑制及其用于预防和治疗神经病症的用途
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2019161302A1 (en) * 2018-02-16 2019-08-22 University Of Southern California Biomarkers for parkinson's disease
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
JP2759895B2 (ja) 1991-08-30 1998-05-28 サノフィ インターロイキン１βプロテアーゼをコードするＤＮＡ配列単離体
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
CA2129976C (en) 1992-02-21 2002-09-17 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
FR2698984B1 (fr) 1992-12-04 1995-01-06 Commissariat Energie Atomique Procédé et dispositif d'acquisition d'une image à trois dimensions d'un petit objet par palpage lumineux et moyen d'étalonnage pour la mise en Óoeuvre d'une telle acquisition.
CA2186511C (en) 1994-03-31 2009-02-10 Roland E. Dolle Pyrimidinyl derivatives as interleukin inhibitors
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
WO1998001133A1 (en) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
DE69734718T2 (de) 1996-09-12 2006-08-24 Idun Pharmaceuticals, Inc., San Diego Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
CA2268098A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
WO1998016504A2 (en) 1996-10-11 1998-04-23 Warner-Lambert Company SULFONAMIDE SUBSTITUTED ASPARTIC ACID INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS
US6316415B1 (en) 1996-10-11 2001-11-13 Basf Aktiengesellschaft Sulfonamide interleukin-1β converting enzyme inhibitors
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
DK1049703T3 (da) 1998-01-20 2003-06-02 Abbott Gmbh & Co Kg N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym
CN1297354A (zh) 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
CA2324226C (en) 1998-03-19 2012-06-05 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
HRP20000744A2 (en) 1998-05-05 2001-06-30 Warner Lambert Co Succinamide inhibitors of interleukin-1beta converting enzyme
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6391575B1 (en) 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
AU765462B2 (en) 1999-03-16 2003-09-18 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
ATE336480T1 (de) 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
WO2000061542A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
WO2001005772A1 (en) 1999-07-19 2001-01-25 Merck Frosst Canada & Co. Pyrazinones, compositions containing such compounds
AU6894800A (en) 1999-08-06 2001-03-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
IL148426A0 (en) 1999-08-27 2002-09-12 Cytovia Inc α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
YU73702A (sh) 2000-03-29 2006-03-03 Vertex Pharmaceuticals Incorporated Karbamatni inhibitori kaspaze i njihova upotreba
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
EP1283827A2 (en) 2000-05-23 2003-02-19 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
US6800619B2 (en) 2000-09-13 2004-10-05 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP4349802B2 (ja) 2000-11-21 2009-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用
EP1381602A1 (en) 2001-04-19 2004-01-21 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
JP2005500996A (ja) 2001-05-10 2005-01-13 アボット ゲーエムベーハー ウント カンパニー カーゲー アリールスルホンアミドエーテルおよびそれの使用方法
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
EP1480999A2 (en) 2002-02-08 2004-12-01 Idun Pharmaceuticals (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
AU2003272189A1 (en) 2002-04-05 2004-01-19 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
BR0312232A (pt) 2002-06-28 2005-05-10 Vertex Pharma Inibidores de caspases e seus usos
EP1581501A1 (en) 2002-12-20 2005-10-05 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PL1633189T3 (pl) * 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
US20050202508A1 (en) 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
US7312361B2 (en) 2005-02-08 2007-12-25 The Scripps Research Institute Inhibitors of transthyretin amyloid fibril formation
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP2009525966A (ja) 2006-01-26 2009-07-16 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送を調節するための化合物および方法
WO2007129221A2 (en) 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
WO2008034016A2 (en) 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
WO2008157425A2 (en) 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120276019A1 (en) * 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
WO2010054127A1 (en) 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20130289022A1 (en) * 2010-11-05 2013-10-31 Brandeis University Tetrameric alpha-synuclein and use thereof
JP6006908B2 (ja) * 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用

Similar Documents

Publication Publication Date Title
US12203943B2 (en) Biomarkers of fast progression of chronic kidney disease
Kim et al. Femtomolar detection of tau proteins in undiluted plasma using surface plasmon resonance
US9134326B2 (en) Biomarkers for liver fibrosis
US10942188B2 (en) Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD
JP2007535930A5 (enExample)
BR112012030788B8 (pt) Anticorpo monoclonal, linhagem celular de hibridoma, e métodos para identificar a presença e para determinação quantitativa de uma enzima aad-12
EP3526605B1 (en) Method for the detection of apolipoprotein e4
JP2022046533A (ja) Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法
JP2015533788A5 (enExample)
JP2012515226A5 (enExample)
WO2008060394A3 (en) Methods and assays for detecting gp73-specific autoantibodies
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
JP2010522875A5 (enExample)
US20230408521A1 (en) Gdf-15 as a diagnostic marker for melanoma
WO2005109000A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
Matsui et al. Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products
TW202200793A (zh) 使用無細胞核小體含量之分診方法
JP2014518624A5 (enExample)
JP2014224759A5 (enExample)
JP2009507471A5 (enExample)
WO2012165926A3 (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
BRPI0606307A2 (pt) formas de fator xlla e métodos para determinar as referidas formas
CA3115887A1 (en) Antibodies specific for glycosylated apoj and uses thereof
CN104937419B (zh) 预测受试者患癌症的风险或诊断癌症的方法
WO2012141792A3 (en) Adiponectin receptor c-terminal fragments (ctf)-immunoglobulin